Preparation method

Disclosed herein are methods of co-formulating amylin receptor agonists and GLP-1 receptor agonists. Disclosed herein are liquid pharmaceutical formulations comprising an amylin receptor agonist, a GLP-1 receptor agonist, and a cyclodextrin comprising a hydroxypropyl substitution. The co-formulation...

Full description

Saved in:
Bibliographic Details
Main Authors R.R.E.HANSEN, KJELDSEN, BJU RN, THOMAS
Format Patent
LanguageChinese
English
Published 15.11.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are methods of co-formulating amylin receptor agonists and GLP-1 receptor agonists. Disclosed herein are liquid pharmaceutical formulations comprising an amylin receptor agonist, a GLP-1 receptor agonist, and a cyclodextrin comprising a hydroxypropyl substitution. The co-formulations may be used in the medical treatment of subjects suffering from: overweight or obesity with or without associated co-diseases; diabetes with or without associated co-diseases; cardiovascular diseases, non-alcoholic steatohepatitis (NASH) and cognitive disorders, such as cognitive disorders caused by Alzheimer's disease. 本文公开了共同配制胰淀素受体激动剂和GLP-1受体激动剂的方法。本文公开了液体药物制剂，其包含胰淀素受体激动剂、GLP-1受体激动剂和包含羟丙基取代的环糊精。所述共制剂可用于患有以下疾病的受试者的医学治疗：伴有或不伴有相关共病的超重或肥胖症；伴有或不伴有相关共病的糖尿病；心血管疾病、非酒精性脂肪性肝炎(NASH)和认知障碍，例如由阿尔茨海默病引起的认知障碍。
Bibliography:Application Number: CN20238032098